October 01, 2016 6:41 PM ET

Biotechnology

Company Overview of Incyte Corporation

Executive Profile

David W. Gryska MBA

Chief Financial Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 12 different industries.

See Board Relationships
61$1,796,589
As of Fiscal Year 2015

Background

Mr. David W. Gryska, also known as Dave, MBA, has been the Chief Financial Officer and Executive Vice President of Incyte Corporation since October 31, 2014. Mr. Gryska has been Strategic Advisor to the Board at Novogen Limited since March 3, 2014. Mr. Gryska served as an Interim Chief Executive Officer of Myrexis Inc., from August 15, 2012 to December 24, 2012. He served as the Chief Operating Officer of Myrexis, Inc., from May 11, 2012 to December 24, 2012 and served ...

Corporate Headquarters

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships

Director
2004-Present
Independent Director and Chairman of Audit Committee
2005-Present
Director and Chairman of Audit Committee
2014-Present
Director, Member of Audit Committee and Member of Nominating & Governance Committee

Education

Unknown/Other Education
Golden Gate University
BA
Loyola University Chicago
Doctorate2010 - 2010
Jawaharlal Nehru Technological University

Other Affiliations

Annual Compensation

Salary$537,366
Total Annual Compensation$537,366

Stocks Options

Restricted Stock Awards$221,241
All Other Compensation$28,000
Exercisable Options$21,535
Exercisable Options Value$891,334
Unexercisable Options$55,386
Unexercisable Options Value$2,159,925
Total Value of Options$3,051,258
Total Number of Options$76,921

Total Compensation

Total Annual Cash Compensation$911,494
Total Short Term Compensation$537,366
Other Long Term Compensation$249,241
Total Calculated Compensation$1,796,589
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman and Chief Executive Officer
Alkermes plc
$881.0K
Jean-Jacques Bienaimé MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
$973.5K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.3M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$869.6K
Randal J. Kirk J.D.Chairman and Chief Executive Officer
Intrexon Corporation
$4.4M
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Incyte Corporation, please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.